Cargando…
Hot topics in Fabry disease
Fabry disease is a rare inborn error of the enzyme α-galactosidase (α-Gal) and results in lysosomal substrate accumulation in tissues with a wide range of clinical presentations. The disease has attracted a lot of interest over the last years, in particular since enzyme replacement therapy (ERT) has...
Autores principales: | Cairns, Tereza, Müntze, Jonas, Gernert, Judith, Spingler, Lisa, Nordbeck, Peter, Wanner, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581083/ https://www.ncbi.nlm.nih.gov/pubmed/30559317 http://dx.doi.org/10.1136/postgradmedj-2018-136056 |
Ejemplares similares
-
Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
por: Müntze, Jonas, et al.
Publicado: (2018) -
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
por: Müntze, Jonas, et al.
Publicado: (2019) -
Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real‐World Data”
por: Müntze, Jonas, et al.
Publicado: (2019) -
Characterization of vertigo and hearing loss in patients with Fabry disease
por: Köping, Maria, et al.
Publicado: (2018) -
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease
por: Köping, Maria, et al.
Publicado: (2017)